Yeung SMH, Binnenmars SH, Gant CM, et al. - In patients with type 2 diabetes (T2D) and normal or mildly impaired kidney function, researchers investigated the link between fibroblast growth factor 23 (FGF23) and adverse outcomes. In 310 individuals with T2D and estimated glomerular filtration rate ≥ 60 mL/min/1.73 m², COOH-terminal FGF23 levels were examined. According to results, 47 patients developed major adverse cardiovascular events, and 28 patients died during a follow-up of 5.8 years (3.3–6.5). Findings suggested an association of FGF23 with an increased risk of cardiovascular events and mortality in patients with T2D and normal or mildly impaired kidney function.